Showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction
Hovione today announced the signing of a partnership agreement with Ligand to significantly ramp up the production output of Captisol®
Effective May 1st, 2020
Hovione announces successful end-of-phase 2 meeting with the FDA and outlines phase 3 program for minocycline topical gel
Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.